CLEAR·OCEAN

Nuvectis Pharma, Inc. (NVCT): insiders bought $1,166,000 in open-market purchases, SEC filings show

July 02, 2026 · Automated from SEC filings

2 insiders at Nuvectis Pharma, Inc. (NVCT) reported open-market stock purchases totaling $1,166,000 in recent weeks, according to filings with the U.S. Securities and Exchange Commission. The largest reported purchase came from Mosseri Marlio Charles (10 percent owner), who acquired 50,000 shares at $18.32 on June 30, 2026.

Reported open-market purchases

Source: SEC Form 4. Option grants and tax-withholding sales are excluded.

DateInsiderRoleSharesPriceValueSource
2026-06-30Mosseri Marlio Charles10 percent owner50,000$18.32$916,000SEC Form 4
2026-06-30BENTSUR RONdirector, 10 percent owner, officer: Chairman & CEO12,500$20.00$250,000SEC Form 4

About the company

Nuvectis Pharma, Inc. is a Healthcare company in the Biotechnology industry. It carried a market capitalization of about $518M, with shares trading near $19.52.

Sources

This article is automated factual reporting of public SEC filings, for informational purposes only. It is not investment advice, nor a recommendation, offer or solicitation to buy or sell any security, and reflects no opinion on the company. Figures are drawn from filings believed reliable but are not guaranteed. Always verify against the primary SEC filing and consult a licensed professional. Investing can lose value, up to total loss.